Updated definitions of healthy ranges for serum alanine aminotransferase levels

被引:1128
作者
Prati, D
Taioli, E
Zanella, A
Della Torre, E
Butelli, S
Del Vecchio, E
Vianello, L
Zanuso, F
Mozzi, F
Milani, S
Conte, D
Colombo, M
Sirchia, G
机构
[1] Osped Maggiore, Ctr Trasfus & Immunol Trapianti, IRCCS, Lab Epidemiol,Div Ematol, I-20122 Milan, Italy
[2] Osped Maggiore, Ist Stat Med & Biometria, IRCCS, Cattedra Gastroenterol, I-20122 Milan, Italy
[3] Osped Maggiore, Ist Med Interna, IRCCS, I-20122 Milan, Italy
[4] Univ Milan, I-20122 Milan, Italy
关键词
D O I
10.7326/0003-4819-137-1-200207020-00006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Serum alanine aminotransferase (ALT) activity, the variable most commonly measured to assess hepatic disease, fails to identify many patients with hepatic injury. Current standards for "normal" ALT level were defined by using populations that included persons with subclinical liver disease. Objective: To update definitions of healthy ranges for serum ALT level. Design: Retrospective cohort study. Setting: A university hospital in Milan, Italy. Participants: 6835 persons who were first-time blood donors from 1995 through 1999, were negative for anti-hepatitis C virus (HCV), and had no contraindications to donation and 209 persons who attempted to donate blood from 1990 through 1999 but were found to have anti-HCV antibodies. Of the latter group, 131 had HCV viremia. Measurements: Univariate and multivariate analyses examined associations between clinical and laboratory factors and ALT levels. Healthy ranges for ALT were computed from the population at lowest risk for liver disease. Sensitivity and specificity of healthy ALT ranges were evaluated in the donors with HCV antibodies, of whom 133 had liver biopsy. Results: Serum ALT activity was independently related to body mass index and to laboratory indicators of abnormal lipid or carbohydrate metabolism. Updated upper limits (for men, 500 nkat/L [30 U/L]; for women, 317 nkat/L [19 U/L]) were lower than current limits (for men, 667 nkat/L [40 U/L]; for women, 500 nkat/L [30 U/L]) and, during 6-month follow-up, showed superior sensitivity in identifying participants with HCV viremia (sensitivity, 76.3% [95 % Cl, 69.1% to 83.6%] vs. 55% [Cl, 46.4% to 63.5%]). The related tradeoff in specificity was acceptable (88.5% [Cl, 79.2% to 94.6%] vs. 97.4% [91% to 99.7%]). The increased sensitivity targeted patients with minimal to mild histologic lesions. Conclusion: In patients with chronic HCV infection or nonalcoholic fatty liver disease, revision of normal limits for ALT level is advisable.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 39 条
  • [1] HEPATITIS-C VIREMIA AND LIVER-DISEASE IN SYMPTOM-FREE INDIVIDUALS WITH ANTI-HCV
    ALBERTI, A
    MORSICA, G
    CHEMELLO, L
    CAVALLETTO, D
    NOVENTA, F
    PONTISSO, P
    RUOL, A
    [J]. LANCET, 1992, 340 (8821) : 697 - 698
  • [2] Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
    Angulo, P
    Keach, JC
    Batts, KP
    Lindor, KD
    [J]. HEPATOLOGY, 1999, 30 (06) : 1356 - 1362
  • [3] [Anonymous], 1998, MMWR Recomm Rep, V47, P1
  • [4] PREVALENCE OF CHRONIC LIVER-DISEASE IN THE GENERAL-POPULATION OF NORTHERN ITALY - THE DIONYSOS STUDY
    BELLENTANI, S
    TIRIBELLI, C
    SACCOCCIO, G
    SODDE, M
    FRATTI, N
    DEMARTIN, C
    CRISTIANINI, G
    ARMOCIDA, C
    BARBANI, A
    BARONI, D
    BRANDI, G
    CROCE, LS
    FERRETTI, I
    FIGLIOLI, GF
    MANENTI, AL
    MANENTI, F
    MARCHEGIANO, P
    MESSORI, B
    PASSAMONTI, S
    POPPI, C
    SASSATELLI, R
    [J]. HEPATOLOGY, 1994, 20 (06) : 1442 - 1449
  • [5] Clinical course and risk factors of hepatitis C virus related liver disease in the general population:: report from the Dionysos study
    Bellentani, S
    Pozzato, G
    Saccoccio, G
    Crovatto, M
    Crocè, LS
    Mazzoran, L
    Masutti, F
    Cristianini, G
    Tiribelli, C
    [J]. GUT, 1999, 44 (06) : 874 - 880
  • [6] Prevalence of and risk factors for hepatic steatosis in northern Italy
    Bellentani, S
    Saccoccio, G
    Masutti, F
    Crocè, LS
    Brandi, G
    Sasso, F
    Cristanini, G
    Tiribelli, C
    [J]. ANNALS OF INTERNAL MEDICINE, 2000, 132 (02) : 112 - 117
  • [7] POSTTRANSFUSION HEPATITIS - IMPACT OF NON-A, NON-B-HEPATITIS SURROGATE TESTS
    BLAJCHMAN, MA
    BULL, SB
    FEINMAN, SV
    [J]. LANCET, 1995, 345 (8941): : 21 - 25
  • [8] Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease
    Caldwell, SH
    Oelsner, DH
    Iezzoni, JC
    Hespenheide, EE
    Battle, EH
    Driscoll, CJ
    [J]. HEPATOLOGY, 1999, 29 (03) : 664 - 669
  • [9] Body-mass index and mortality in a prospective cohort of US adults
    Calle, EE
    Thun, MJ
    Petrelli, JM
    Rodriguez, C
    Heath, CW
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (15) : 1097 - 1105
  • [10] Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection
    ConryCantilena, C
    VanRaden, M
    Gibble, J
    Melpolder, J
    Shakil, AO
    Viladomiu, L
    Cheung, L
    DiBisceglie, A
    Hoofnagle, J
    Shih, JW
    Kaslow, R
    Ness, P
    Alter, HJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (26) : 1691 - 1696